Enable Injections Holds First Closing of Series B Round

enableEnable Injections, Inc., a Cincinnati, OH-based combination products company developing advanced wearable devices for subcutaneous delivery of biologics and other high volume therapeutics, completed a first closing of a Series B round that will raise up to $50M.

The round was led by Sanofi, with participation from previous investors ORI Healthcare Fund, CincyTech, Cincinnati Children’s Hospital, Cintrifuse, Ohio Innovation Fund, Cleveland Clinic and key private investors.

The company intends to use the funds to scale from existing clinical production to high-volume, large scale commercial manufacturing of enFuse™ drug delivery platform.

Led by Michael D. Hooven, President and CEO, Enable Injections develops and manufactures wearable drug delivery devices that allow patient self-administration of large volume/high viscosity drugs in doses from 5 mL to 50 mL.
Its body-worn enFuse™ drug delivery platform utilizes any standard container closure system, including syringes or vials; automatically warms and can automatically mix lyophilized solutions.



Join the discussion